Literature DB >> 19558363

Enhanced protection of Ins-1 beta cells from apoptosis under hypoxia by delivery of DNA encoding secretion signal peptide-linked exendin-4.

Hyun Ah Kim1, Suyeon Lee, Jeong-Hyun Park, Sanghyun Lee, Byung-Wan Lee, Sung Hee Ihm, Tae-il Kim, Sung Wan Kim, Kyung Soo Ko, Minhyung Lee.   

Abstract

In this study, we developed an expression system of exendin-4, a glucagon-like peptide (GLP-1) analog, using a secretion signal peptide (SP) to facilitate exendin-4 secretion. For delivery of the exendin-4 expression system, high-molecular-weight polyethylenimine (25 kDa, PEI25k), low-molecular-weight polyethylenimine (2 kDa, PEI2k), and polyamidoamine (PAMAM) dendrimers were evaluated as gene carriers to Ins-1 beta cells. As a result, PEI25k showed the highest transfection efficiency. For the construction of the exendin-4 expression vector, DNA coding the SP sequence was inserted upstream of the exendin-4 cDNA, resulting in the construction of pbeta-SP-Ex-4. Transfection assay showed that the secretion level of exendin-4 increased in the pbeta-SP-Ex-4 transfected cells, compared with the pbeta-Ex-4 transfected cells. To identify the beta-cell protection effect of pbeta-SP-Ex-4 delivery, the Ins-1 beta cells were transfected with pbeta-SP-Ex-4 or pbeta-Ex-4 and incubated under normoxia or hypoxia. An MTT assay showed that the pbeta-SP-Ex-4 transfected cells had higher beta-cell viability than the pbeta-Ex-4 transfected cells under hypoxia. In addition, the pbeta-SP-Ex-4 transfected cells exhibited lower caspase-3 activity than the pbeta-Ex-4 transfected cells. Therefore, PEI25k/pbeta-SP-Ex-4 complex may be useful to protect isolated beta cells from apoptosis during transplantation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19558363     DOI: 10.1080/10611860902718664

Source DB:  PubMed          Journal:  J Drug Target        ISSN: 1026-7158            Impact factor:   5.121


  5 in total

1.  Delivery of two-step transcription amplification exendin-4 plasmid system with arginine-grafted bioreducible polymer in type 2 diabetes animal model.

Authors:  Pyung-Hwan Kim; Minhyung Lee; Sung Wan Kim
Journal:  J Control Release       Date:  2012-06-15       Impact factor: 9.776

2.  Post-translational regulated and hypoxia-responsible VEGF plasmid for efficient secretion.

Authors:  Young-Wook Won; Minhyung Lee; Hyun Ah Kim; David A Bull; Sung Wan Kim
Journal:  J Control Release       Date:  2012-03-16       Impact factor: 9.776

3.  Nanomedicines for Endothelial Disorders.

Authors:  Bomy Lee Chung; Michael J Toth; Nazila Kamaly; Yoshitaka J Sei; Jacob Becraft; Willem J M Mulder; Zahi A Fayad; Omid C Farokhzad; YongTae Kim; Robert Langer
Journal:  Nano Today       Date:  2015-12-01       Impact factor: 20.722

4.  Maintenance of ischemic β cell viability through delivery of lipids and ATP by targeted liposomes.

Authors:  Nicole Atchison; Garrett Swindlehurst; Klearchos K Papas; Michael Tsapatsis; Efrosini Kokkoli
Journal:  Biomater Sci       Date:  2014-04-01       Impact factor: 6.843

5.  Enhanced Incretin Effects of Exendin-4 Expressing Chimeric Plasmid Based On Two-Step Transcription Amplification System with Dendritic Bioreducible Polymer for the Treatment of Type 2 Diabetes.

Authors:  Pyung-Hwan Kim; Minhyung Lee; Kihoon Nam; Sung Wan Kim
Journal:  J Gene Ther       Date:  2013-12-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.